Exact Sciences
Exact Sciences Solidifies MRD and Multi-Cancer Screening Plans as Q4 Revenues Rise 10 Percent
Premium
Growth was mainly driven by an increase in colorectal cancer screening revenue, while precision oncology testing income was flat year over year.
Flatiron Health, Exact Sciences Partner on Study of Molecular Residual Disease Test
The collaborators have enrolled their first patient in a prospective clinical study testing a tumor-informed assay for monitoring recurrence across multiple cancers.
Barclays Initiates Coverage of Guardant Health, Exact Sciences, Natera With Overweight Rating
The investment firm cited large, unpenetrated markets for liquid biopsy in residual disease detection, monitoring, and screening.
JP Morgan Healthcare Conference, Day 1: Exact Sciences, Revvity, Qiagen, Guardant Health, Waters
Highlights from the first day included updates from Exact Sciences about its plans for new tests slated for this year and beyond.
Top Five Articles on 360Dx Last Week: Agilent Reorganizes; Guardant Health Awarded $292.5M; More
Last week, readers were most interested in a story about Agilent changing two of its three business organizations to accelerate growth.
Oct 29, 2024
Oct 1, 2024
360Dx Top 30 Inches up 1 Percent in September
Sep 3, 2024
360Dx Top 30 Ticks up 2 Percent in August
Jun 4, 2024